摘要:
Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
摘要:
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
摘要:
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
摘要:
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
摘要:
A novel keyboard interface and input method are described. The interface is driven by a dynamic, general-purpose typing and data-entry software application, with a reduced number of keys to minimize screen real-estate requirements, especially for mobile devices. At any given time, the interface presents base characters with built-in key points on or around the base characters that can be selected and/or swiped to generate characters. The key points are strategically placed based on the intuitiveness of such placements, reducing the curve for learning how to use the interface. Its advantage over other methods of input such as handwriting, voice and gesture recognition is that it is less prone to error and privacy issues. The interface occupies a dramatically smaller area of the screen compared to traditional on-screen keyboards and can provide alternate placement as well as transparency to reveal text or images underneath. It can be implemented in most mobile and other computing platforms with reduced resource requirements.
摘要:
The invention relates to a driver circuit used to transmit a digital signal from a source device to a destination device. The driver circuit provides a controlled switching time to improve digital signal quality, while reducing electromagnetic interference. In the circuit, a pair of first switches of a first plurality are coupled in parallel between a first current node and respective ones of first and second output terminals. A plurality of pairs of second switches of a second plurality are coupled in parallel between a respective second current node and the first and second output terminals. Timing circuitry applies input signals to the pair of first switches and successive input signals to the pairs of second switches so as to develop a staggered voltage across a load coupled between the first and second output terminals.
摘要:
The invention relates to a driver circuit used to transmit a digital signal from a source device to a destination device. The driver circuit provides a controlled switching time to improve digital signal quality, while reducing electromagnetic interference. In the circuit, a pair of first switches of a first plurality are coupled in parallel between a first current node and respective ones of first and second output terminals. A plurality of pairs of second switches of a second plurality are coupled in parallel between a respective second current node and the first and second output terminals. Timing circuitry applies input signals to the pair of first switches and successive input signals to the pairs of second switches so as to develop a staggered voltage across a load coupled between the first and second output terminals.
摘要:
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
摘要:
The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
摘要:
Dry powder pharmaceutical formulations for pulmonary or nasal administration are made to provide an improved respired dose. These formulations may be blends of milled blends and may include a phospholipid, alone or in combination with other excipient materials. In one case, the process includes the steps of (a) providing particles which comprise a pharmaceutical agent, (b) blending the particles with particles of at least one first excipient to form a first powder blend; (c) milling the first powder blend to form a milled blend which comprises microparticles or nanoparticles of the pharmaceutical agent; and (d) blending the milled blend with particles of a second excipient to form a blended dry powder blend pharmaceutical formulation suitable for pulmonary or nasal administration.